Dipartimento di Scienze Farmaceutiche, Via Fossato di Mortara 17-19, Università di Ferrara, 44121 Ferrara, Italy.
Bioorg Med Chem. 2012 Jan 15;20(2):996-1007. doi: 10.1016/j.bmc.2011.11.044. Epub 2011 Dec 1.
In a preliminary article, we reported the potent allosteric enhancer activity at the A(1) adenosine receptor of a small series of 2-amino-3-(4-chlorobenzoyl)-4-[4-(aryl)piperazin-1-yl)methyl]thiophene derivatives bearing electron-withdrawing or electron-releasing groups at the para-position of the phenylpiperazine moiety. In the present study, we report the development of the compounds previously studied by modifying both the number and position of substituents on the phenylpiperazine moiety, aimed at establishing a structure-activity relationship identifying additional compounds with improved activity. The nature and the position of substituents on the phenyl ring tethered to the piperazine seemed to exert a fundamental influence on the allosteric enhancer activity, with the 3,4-difluoro 4i, 3-chloro-4-fluoro 4o, and 4-trifluoromethoxy 4ak derivatives being the most active compounds in binding (saturation and competition experiments) and functional cAMP studies. This study shows that it is also possible to obtain a good separation between allosteric enhancement and antagonistic activity at the A(1) adenosine receptor.
在一篇初步的文章中,我们报道了一系列 2-氨基-3-(4-氯苯甲酰基)-4-[4-(芳基)哌嗪-1-基甲基]噻吩衍生物在 A(1)腺苷受体上的有效变构增强活性,这些衍生物在苯哌嗪部分的对位带有吸电子或供电子基团。在本研究中,我们通过修饰苯哌嗪部分的取代基的数量和位置,对以前研究的化合物进行了开发,旨在建立一个结构-活性关系,确定具有改善活性的额外化合物。与哌嗪相连的苯环上取代基的性质和位置似乎对变构增强活性有根本影响,带有 3,4-二氟 4i、3-氯-4-氟 4o 和 4-三氟甲氧基 4ak 取代基的化合物在结合(饱和和竞争实验)和功能性 cAMP 研究中是最活跃的化合物。这项研究表明,也有可能在 A(1)腺苷受体上获得变构增强和拮抗活性之间的良好分离。